(Q35557605)

English

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer.

scientific article published on 6 February 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

0 references

1 reference

Europe PubMed Central

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

Gerlinde Pilkington

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Angela Boland

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Tamara Brown

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

James Oyee

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Adrian Bagust

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Rumona Dickson

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

0 references

publication date

6 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

70

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

359-367

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25661113%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review.

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical T

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Aggregate data meta-analysis with time-to-event outcomes

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung can

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status.

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1136%2FTHORAXJNL-2014-205914

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35557605&oldid=1525253619"